表紙
市場調査レポート

ワルデンシュトレームマクログロブリン血症 : パイプライン分析

Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213065
出版日 ページ情報 英文 214 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
ワルデンシュトレームマクログロブリン血症 : パイプライン分析 Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016
出版日: 2016年04月20日 ページ情報: 英文 214 Pages
概要

ワルデンシュトレームマクログロブリン血症(WM)とは、マクログロブリンと呼ばれる異常なタンパク質が大量に作られる非ホジキンリンパ腫(NHL)の一種で、年齢、性別、家族歴、C型肝炎、特定の自己免疫疾患などがリスクファクターとしてあります。特にシェーグレン症候群などは特に高いリスクがあります。治療には、幹細胞移植、生物学的治療、化学療法、放射線治療などがあります。

当レポートでは、世界におけるワルデンシュトレームマクログロブリン血症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および彼らが開発中の製品のレビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

ワルデンシュトレームマクログロブリン血症の概要

治療薬の開発

  • ワルデンシュトレームマクログロブリン血症向けパイプライン製品:概要
  • ワルデンシュトレームマクログロブリン血症向けパイプライン製品:比較分析

ワルデンシュトレームマクログロブリン血症:開発中の治療薬:企業別

ワルデンシュトレームマクログロブリン血症:開発中の治療薬:大学・研究機関別

ワルデンシュトレームマクログロブリン血症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

ワルデンシュトレームマクログロブリン血症:開発中の製品:企業別

ワルデンシュトレームマクログロブリン血症:開発中の製品:大学・研究機関別

ワルデンシュトレームマクログロブリン血症:治療薬開発に従事している企業

  • AbbVie Inc.
  • arGEN-X BV
  • Bayer AG
  • BeiGene(Beijing) Co.,Ltd
  • Calithera Biosciences, Inc.
  • Celgene Corporation
  • Genentech, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Hutchison MediPharma Limited
  • Idera Pharmaceuticals, Inc.
  • IGF Oncology, LLC.
  • Incyte Corporation
  • Karyopharm Therapeutics, Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Onyx Pharmaceuticals, Inc.

ワルデンシュトレームマクログロブリン血症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (INCB-039110+INCB-040093)
  • 765IGF-MTX
  • acalabrutinib
  • ARGX-110
  • BGB-3111
  • カーフィルゾミブ
  • CB-839
  • copanlisib hydrochloride
  • DI-B4
  • entospletinib
  • エベロリムス
  • FV-162
  • FV-214
  • HMPL-523
  • idelalisib
  • IMO-8400
  • INCB-39110
  • INCB-40093
  • INCB-50465
  • ixazomib citrate
  • lenalidomide
  • オファツムマブ
  • oprozomib
  • pevonedistat hydrochloride
  • selinexor
  • 免疫学・腫瘍学向け IRAK4 阻害小分子
  • spebrutinib besylate
  • venetoclax
    • 製品概要
    • 作用機序
    • R&Dの進捗

ワルデンシュトレームマクログロブリン血症:最近のパイプライン動向

ワルデンシュトレームマクログロブリン血症:休止中のプロジェクト

ワルデンシュトレームマクログロブリン血症:開発が中止された製品

ワルデンシュトレームマクログロブリン血症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7840IDB

Summary

Global Markets Direct's, 'Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016', provides an overview of the Waldenstrom Macroglobulinemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Waldenstrom Macroglobulinemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia
  • The report reviews pipeline therapeutics for Waldenstrom Macroglobulinemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Waldenstrom Macroglobulinemia therapeutics and enlists all their major and minor projects
  • The report assesses Waldenstrom Macroglobulinemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Waldenstrom Macroglobulinemia Overview
  • Therapeutics Development
    • Pipeline Products for Waldenstrom Macroglobulinemia - Overview
  • Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies
  • Waldenstrom Macroglobulinemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Waldenstrom Macroglobulinemia - Products under Development by Companies
  • Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Amgen Inc.
    • arGEN-X BV
    • Aurigene Discovery Technologies Limited
    • Bayer AG
    • BeiGene, Ltd.
    • Calithera Biosciences, Inc.
    • Celgene Corporation
    • Genentech, Inc.
    • Gilead Sciences, Inc.
    • Hutchison MediPharma Limited
    • Idera Pharmaceuticals, Inc.
    • IGF Oncology, LLC.
    • Incyte Corporation
    • Juno Therapeutics Inc.
    • Karyopharm Therapeutics, Inc.
    • Merck KGaA
    • Millennium Pharmaceuticals, Inc.
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Vivolux AB
  • Waldenstrom Macroglobulinemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (INCB-039110 + INCB-040093) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 765IGF-MTX - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • acalabrutinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARGX-110 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BGB-3111 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bortezomib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CA-4948 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-839 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • copanlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DI-B4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • entospletinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-523 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMO-8400 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-40093 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-50465 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • itacitinib adipate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixazomib citrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JCAR-015 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ofatumumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oprozomib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • spebrutinib besylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • venetoclax - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VLX-1570 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Waldenstrom Macroglobulinemia - Recent Pipeline Updates
  • Waldenstrom Macroglobulinemia - Dormant Projects
  • Waldenstrom Macroglobulinemia - Discontinued Products
  • Waldenstrom Macroglobulinemia - Product Development Milestones
    • Featured News & Press Releases
      • May 27, 2015: Amgen To present data from Oprozomib study at the 20th Congress of the EHA
      • Nov 07, 2013: Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations On Oprozomib at 55th American Society of Hematology Annual Meeting
      • Apr 01, 2013: Onyx Pharma To Present Data On Oprozomib At 14th International Myeloma Workshop
      • Nov 06, 2012: Onyx Pharma Announces Data Presentations On Oprozomib At 54th American Society Of Hematology Annual Meeting
      • Nov 08, 2011: Genmab To Present Data On Ofatumumab At 53rd American Society Of Hematology Annual Meeting And Exposition
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Waldenstrom Macroglobulinemia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc., H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Amgen Inc., H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV, H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by BeiGene, Ltd., H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Genentech, Inc., H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Idera Pharmaceuticals, Inc., H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by IGF Oncology, LLC., H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Juno Therapeutics Inc., H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Merck KGaA, H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Vivolux AB, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Waldenstrom Macroglobulinemia Therapeutics - Recent Pipeline Updates, H1 2016
  • Waldenstrom Macroglobulinemia - Dormant Projects, H1 2016
  • Waldenstrom Macroglobulinemia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Waldenstrom Macroglobulinemia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top